NEW YORK – Kyverna Therapeutics on Wednesday announced a multiyear pact with Charité-Universitätsmedizin Berlin's rheumatology and clinical immunology department to fund research into the impact of cell-targeting therapeutics on patients with systemic autoimmune diseases.
Emeryville, California-based Kyverna and Charité-Universitätsmedizin will study the effects of B- and plasma cell-targeting therapies on the immunologic profile and clinical outcomes of patients treated at the German hospital with systemic autoimmune diseases. That includes KYV-101, an autologous CAR T-cell therapy Kyverna is testing in multiple autoimmune diseases.
Investigators will assess changes in circulating and tissue resident B cell and plasma cell subsets, T cells, and other immune cells in peripheral blood before and after treatments.
The two organizations will jointly own the results stemming from the research effort. Financial details of the collaboration were not disclosed.